Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR | P35968 | 5/20 | 0.46 |
| ▸ | TNK2 | Q07912 | 1/20 | 0.40 |
| ▸ | FLT1 | P17948 | 7/20 | 0.39 |
| ▸ | PLK4 | O00444 | 3/20 | 0.39 |
| ▸ | ROCK2 | O75116 | 3/20 | 0.39 |
| ▸ | MAP4K4 | O95819 | 3/20 | 0.39 |
| ▸ | LCK | P06239 | 3/20 | 0.39 |
| ▸ | LYN | P07948 | 3/20 | 0.39 |
| ▸ | RET | P07949 | 3/20 | 0.39 |
| ▸ | FLT4 | P35916 | 3/20 | 0.39 |
| ▸ | FLT3 | P36888 | 3/20 | 0.39 |
| ▸ | FRK | P42685 | 3/20 | 0.39 |
| ▸ | CSNK1D | P48730 | 3/20 | 0.39 |
| ▸ | BLK | P51451 | 3/20 | 0.39 |
| ▸ | IRAK1 | P51617 | 3/20 | 0.39 |
| ▸ | NEK2 | P51955 | 3/20 | 0.39 |
| ▸ | LIMK1 | P53667 | 3/20 | 0.39 |
| ▸ | CSNK1G2 | P78368 | 3/20 | 0.39 |
| ▸ | MAP4K2 | Q12851 | 3/20 | 0.39 |
| ▸ | STK3 | Q13188 | 3/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3126763 | 0.76 | KDR (0.50) | KDRTNK2FLT1PLK4ROCK2 | |
| SCHEMBL14013981 | 0.74 | KDR (0.68) | KDRFLT1PLK4ROCK2MAP4K4 | |
| SCHEMBL6928152 | 0.72 | KDR (0.47) | KDRTNK2FLT1PLK4ROCK2 | |
| SCHEMBL2976034 | 0.69 | KDR (0.67) | KDRTNK2FLT1PLK4ROCK2 | |
| SCHEMBL3120400 | 0.69 | KDR (0.71) | KDRFLT1PLK4ROCK2MAP4K4 | |
| SCHEMBL14013994 | 0.67 | KDR (0.68) | KDRTNK2FLT1PLK4ROCK2 | |
| SCHEMBL758987 | 0.67 | CSNK2A1 (0.34) | KDRAURKBHIPK2AURKA | |
| SCHEMBL14014013 | 0.65 | KDR (0.57) | KDRTNK2FLT1PLK4ROCK2 | |
| Gw642125X SCHEMBL14013971 | 0.64 | KDR (1.00) | KDRFLT1PLK4ROCK2MAP4K4 | |
| SCHEMBL14013991 | 0.63 | KDR (0.61) | KDRTNK2FLT1PLK4ROCK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4306529-B1 | FGFR INHIBITORS AND METHODS OF USE THEREOF | RELAY THERAPEUTICS INC (US) | 2026-01-21 | — | — | EP | disclosed |
| US-12522605-B2 | FGFR inhibitors and methods of use thereof | RELAY THERAPEUTICS, INC. (US) | 2026-01-13 | — | — | US | disclosed |
| CN-119874707-A | FGFR inhibitors and methods of use thereof | 传达治疗有限公司 | 2025-04-25 | — | — | CN | disclosed |
| CN-114126620-B | FGFR inhibitors and methods of use thereof | 传达治疗有限公司 | 2024-12-31 | — | — | CN | disclosed |
| EP-4306529-A2 | FGFR INHIBITORS AND METHODS OF USE THEREOF | Relay Therapeutics, Inc. (US) | 2024-01-17 | — | — | EP | disclosed |
| EP-4306529-A2 | FGFR INHIBITORS AND METHODS OF USE THEREOF | Relay Therapeutics, Inc. (US) | 2024-01-17 | — | — | EP | disclosed |
| EP-3968999-B1 | FGFR INHIBITORS AND METHODS OF USE THEREOF | RELAY THERAPEUTICS INC (US) | 2023-12-27 | — | — | EP | disclosed |
| US-11780845-B2 | FGFR inhibitors and methods of use thereof | RELAY THERAPEUTICS, INC. (US) | 2023-10-10 | — | — | US | disclosed |
| US-11780845-B2 | FGFR inhibitors and methods of use thereof | RELAY THERAPEUTICS, INC. (US) | 2023-10-10 | — | — | US | disclosed |
| US-20230192709-A1 | FGFR INHIBITORS AND METHODS OF USE THEREOF | RELAY THERAPEUTICS, INC. | 2023-06-22 | — | — | US | disclosed |
| US-20230192709-A1 | FGFR INHIBITORS AND METHODS OF USE THEREOF | RELAY THERAPEUTICS, INC. | 2023-06-22 | — | — | US | disclosed |
| US-20230104574-A1 | FGFR INHIBITORS AND METHODS OF USE THEREOF | D.E. SHAW RESEARCH, LLC | 2023-04-06 | — | — | US | disclosed |
| EP-3968999-A1 | FGFR INHIBITORS AND METHODS OF USE THEREOF | Relay Therapeutics, Inc. (US) | 2022-03-23 | — | — | EP | disclosed |
| WO-2020231990-A1 | FGFR INHIBITORS AND METHODS OF USE THEREOF | RELAY THERAPEUTICS, INC. (US) | 2020-11-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230192709-A1 | FGFR INHIBITORS AND METHODS OF USE THEREOF | FGFR3, FGFR2, FGFR1 | KDR 80/4885TNK2 346/4885FLT1 45/4885 |
| US-20230104574-A1 | FGFR INHIBITORS AND METHODS OF USE THEREOF | FGFR3, FGFR2, FGFR1 | KDR 80/4885TNK2 346/4885FLT1 45/4885 |
| US-11780845-B2 | FGFR inhibitors and methods of use thereof | FGFR3, FGFR2, FGFR1 | KDR 80/4885TNK2 346/4885FLT1 45/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.